Objective-The leukocyte integrin Mac-1 (␣ M ␤ 2 , CD11b/CD18) binds a number of ligands and counter-receptors and thereby is a major determinant in regulation of leukocyte adhesion and extravasation. Vitronectin (VN) is an adhesion-promoting factor that is abundantly present as matrix molecule in vascular diseases such as atherosclerosis. Until now, only an indirect interaction between Mac-1 and VN via the urokinase receptor (urokinase plasminogen activator receptor) was known. We now propose that Mac-1 and VN can directly interact with each other. Methods and Results-In an in vitro system with purified components, Mac-1 specifically bound the multimeric matrix form of VN but not the monomeric plasma form. Using various competitors, the interaction domains in Mac-1 and VN were localized. Mac-1-expressing but not untransfected Chinese hamster ovary cells adhered strongly on VN.
L eukocyte rolling, adhesion, transmigration, and retention in inflammatory processes is dependent on a number of receptor ligand-counter-receptor systems on the leukocytes, endothelial cells, and the underlying matrix. 1 The classical adhesion receptors on leukocytes are the integrins, of which the ␤ 2 integrin family is specifically expressed on these cells. All ␤ 2 integrins share a common ␤ subunit CD18 (␤ 2 ) and 1 of 4 ␣ subunits that is different in each family member. 2, 3 In Mac-1, the ␤ 2 subunit is in association with CD11b (␣ M ) and binds various ligands such as intercellular cell adhesion molecule-1 (ICAM-1), 4 fibrinogen (FBG), 5 complement protein iC3b, 6 Factor X, 7 heparin sulfate proteoglycans, 8 kininogen, 9 fibronectin (FN), 10 urokinase (urokinase plasminogen activator [uPA]) 11 and its receptor (uPA receptor [uPAR] , CD87), 12 and metal ions. 13 These interactions are not only relevant for cell adhesion but also for other cellular processes such as internalization, phagocytosis, degradation, or pericellular proteolysis. 14, 15 Once leukocytes have crossed the endothelial barrier, several adhesion steps lead to their retention in the inflamed regions. This part of the recruitment process is dependent on the interaction of the leukocyte integrins with certain extracellular matrix molecules such as collagens, laminins, FN, and proteoglycans. Because of the enhanced permeability of the endothelial layer, there is also leakage of plasma proteins such as FBG or vitronectin (VN) that become deposited as a provisional matrix and also serve as substrates for leukocyte adhesion. 16 Furthermore, VN production has been demonstrated in smooth muscle cells in atheromatous plaques. 17, 18 VN exists in a so-called native conformation, circulating in the plasma and in the extracellular matrix as a heparinbinding multimer. 19 Among several mechanisms that regulate activation of ␤ 2 integrins on leukocytes 20, 21 are cell membrane proteins such as the urokinase receptor (uPAR/CD87) 22 that can increase the activity of Mac-1 by a direct binding interaction. 12, 23, 24 Moreover, uPAR can also bind directly to VN, 25 and it has been demonstrated that uPAR serves a bridging function between Mac-1 and VN. 24 The interaction of VN with the typical cell adhesion mediating ␤ 1 , ␤ 3, and ␤ 5 integrins is mediated through its RGD 26 sequence, whereas uPAR interacts with the somatomedin B domain of VN. 27 Because the leukocyte receptor Mac-1 binds to several matrix components, we hypothesized that VN may serve as a direct ligand of the promiscuous Mac-1 (␤ 2 ) integrin. Indeed, through binding studies with purified components as well as cell adhesion studies using Mac-1-transfected cells and neutrophils, we demonstrate that VN is a novel functional ligand for Mac-1.
Materials and Methods

Reagents
Native and multimeric VN was prepared from human plasma as described previously. 28 Chinese hamster ovary (CHO) cell-derived recombinant soluble uPAR and anti-uPAR monoclonal antibody (mAb) R3 was generously given by Dr Niels Behrendt (Finsen Laboratory, Copenhagen, Denmark). The integrin ␣ V ␤ 5 was obtained from Dr Simon Goodman (Merck KGaA, Darmstadt, Germany). Anti-VN mAb 13H1 and active plasminogen activator inhibitor-1 (PAI-1) was given by Dr Paul Declerk (University of Leuven, Belgium), and cleaved PAI-1 was from Dr Peter Andreasen (University of Aarhus, Denmark). VN fragments 1-44 and 1-48 isolated from human hemofiltrate were given by Dr Ludger Ständker 29 (IPF Pharmaceuticals, Hannover, Germany). mAb IB4 against human ␤ 2 integrin (CD18) subunit was from Pharmingen (Hamburg, Germany), and the antibody LPM19c against ␣ M (CD11b) as well as anti-CD29 was from DAKO (Gloestrup, Denmark). Anti-␣ V ␤ 3 and anti-␣ V ␤ 5 antibodies were from Chemicon (Temecula, Calif). Anti-CD61, anti-CD51, and anti-CD11a antibodies were from Immunotech (Marseille, France). Agarose (NEEO, ultraquality) was from Roth (Karlsruhe Germany), and BSA, heparin, human FBG, and FN were from Sigma (Taufkirchen, Germany). Linear RGD and RGE peptides were from Calbiochem (Darmstadt, Germany). Peptide VN-2 (VN 39-51; CKPQVTRGDVFTM) was custom synthesized.
Binding Interactions in a Purified System
Mac-1 and LFA-1 was generously provided by Dr S. Bodary (Genentech, San Francisco, Calif). The preparation of Mac-1 and LFA-1 and the procedures for binding studies are described in supplemental information (detailed Methods, purification of Mac-1 and LFA1-1 and binding interactions in a purified system, available online at http://atvb.ahajournals.org).
Isolation of Neutrophils
Isolation of neutrophils and flow cytometry of neutrophils with anti-integrin antibodies is described in supplemental information (online Methods, isolation of neutrophils as well as flow cytometry; Figure II , available online at http://atvb.ahajournals.org).
Construction of Mac-1 Transfected CHO Cells and Their Cultivation
Two CHO cell lines were generated expressing recombinant Mac-1 either as a wild-type (WT) integrin (Mac-1 WT) or as a mutant (Mac-1 Del) with a GFFKR deletion of the ␣ M subunit. This deletion mutant leads to the constitutive activation of integrin and promotes ligand binding. 30, 31 Details of these procedures are presented in supplemental information (detailed Methods, construction of Mac-1-transfected CHO cells and their cultivation).
Cell Adhesion and Migration
Procedures for cell adhesion and migration are described in supplemental online information (detailed Methods, cell adhesion and cell migration).
Results
Specific Binding of VN to Mac-1
To investigate the possible interaction between VN and Mac-1, binding studies were performed with purified proteins in an ELISA format. Mac-1 and LFA-1 were immobilized, and the binding of native and multimeric form of VN was investigated. Multimeric VN bound to Mac-1 but not to LFA-1-or BSA-coated wells ( Figure 1A ). The binding of multimeric VN was saturable at Ϸ1 g/mL, indicative of a specific ligand-receptor interaction ( Figure 1B) . No binding of native VN was observed at concentrations Ͻ1 g/mL, but at concentrations Ͼ10 g/mL, there was a progressive binding of native VN. This might be attributable to the presence of small amounts of multimeric VN in the native VN preparation. Based on these results, in subsequent experiments, only the extracellular matrix-associated multimeric VN was used.
VN binding to Mac-1 was inhibited by cation-chelating agents such as EDTA, indicating that this was a divalent cation-dependent interaction (Figure 2A ). Although heparin binds to multimeric VN and Mac-1, it had no influence on the binding interaction between the 2 components ( Figure 2A ). FBG is a prominent ligand for Mac-1 as well, and we tested whether both ligands could influence each other in binding to Mac-1. FBG could inhibit VN binding to Mac-1 with an IC 50 of Ϸ100 g/mL ( Figure 2B ). Conversely, the divalent cationdependent FBG binding to Mac-1 ( Figure 2C In additional experiments, no influence of uPA or uPAR, alone or in a complex, on the binding interaction between VN and Mac-1 was observed (data not shown).
Adhesion of Mac-1-Transfected CHO Cells on VN
The above experiments indicate that there is a specific interaction between VN and Mac-1, and this was subsequently tested in adhesion assays using CHO cells transfected with WT Mac-1 (Mac-1 WT) or with a deletion mutant of Mac-1 (Mac-1 Del) that represent a receptor in a constitutively high-affinity conformation. 30, 33 Untransfected CHO cells, Mac-1 WT, or Mac-1 Del exhibited very little adhesion to agarose-blocked plastic. On a VN-coated surface, a strong adhesion was observed with Mac-1 WT cells, and this adhesion could be inhibited by anti-CD18 (IB4) or antiCD11b (LPM19c) antibodies but not by a control antibody ( Figure 3A) . Moreover, the Mac-1 Del-expressing cells exhibited higher adhesion than the cells expressing the WT receptor ( Figure 3A) . To examine the expression of other integrins, for which VN binding has been described, we determined the cell surface expression in flow cytometry ( Figure I ). The integrin ␣ V ␤ 5 was relatively highly expressed, and only minor expression was detected for ␣ V ␤ 3 and ␤ 1 integrins. The expression levels of these integrins were identical in the 3 CHO cell lines compared with one another. Therefore, the transfection and expression of Mac-1 WT or Mac-1 mutant did not alter the integrin expression pattern on CHO cells. Then we evaluated the relative contribution of these integrins to VN-mediated cell adhesion using the cell line that demonstrated the strongest adhesion to VN: the Mac-1 Del CHO cell line ( Figure 3B ). Consistent with the expression levels of the evaluated ␣ V -integrins, different contributions of these integrins to the cell adhesion on VN could be demonstrated. ␣ V ␤ 5 -mediated adhesion was nearly as strong as Mac-1-mediated adhesion. The blockade of both integrin receptors resulted in the strongest inhibition of cell adhesion.
Adhesion and Migration of Human Peripheral Blood Neutrophils on VN
Finally, we tested whether the described adhesion phenomenon was relevant to native human neutrophils and whether it was a determinant of cell migration. Neutrophils adhered to VN-and FBG-coated wells, and this adhesion was stimulated with PMA. Adhesion was abrogated in the presence of anti-CD18 IgG but not control IgG. The extent of adhesion on both substrates in the absence or presence of PMA stimulation was identical ( Figure 4A and 4B) . The removal of divalent cations also abrogated the adhesion under all condi- tions, whereas PAI-1 was without any effect ( Figure 4A and 4B), indicating a lack of contribution of uPAR-dependent adhesion in this system. PMA stimulation of cells increased the surface expression of CD11b but not of other integrins or subunits thereof ( Figure II) . Neutrophils exhibited chemotaxis in response to an FMLP gradient when the filters were coated with FBG or VN. On both surfaces, there was a strong inhibition of cell migration with anti-CD11b antibody but not anti-uPAR antibody. Although anti-VN antibody did not influence cell migration on a FBG-coated surface, there was inhibition of migration on a VN-coated surface ( Figure 4C ).
Discussion
The integrin Mac-1 was identified as a receptor for the extracellular matrix form of VN. 5 cells/well) were allowed to adhere on VN (2 g/mL; A) or FBG (10 g/mL; B) without any treatment (dotted bars) or stimulated with PMA (50 ng/mL; hatched bars) in the absence (Ϫ) or presence of anti-CD18 mAb (IB4; 10 g/mL), control IgG (10 g/mL), EDTA (5 mmol/L), or active PAI-1 (200 nM) as indicated. Cell adhesion is expressed as a percentage of input cells (meanϮSEM; nϭ3). C, Neutrophils (25ϫ10 3 cells/well) were allowed to migrate across filters (3-m pore size) coated with VN (2 g/mL; dotted bars) or FBG (10 g/mL; hatched bars). Where indicated, FMLP was added to a final concentration of 1 mol/L in the lower wells, and cells were incubated with the indicated antibodies at a concentration of 10 g/mL for anti-CD11b and 50 g/mL for anti-VN mAb 13H1 or anti-uPAR mAb R3. Cell migration is expressed as density in arbitrary units (meanϮSEM; nϭ3). Similar results were obtained in 3 separate experiments.
metal ion-dependent and could be inhibited by blocking antibodies against ␤ 2 integrin. The key overlapping binding site in Mac-1 for metal ions ICAM-1, FBG, or iC3b is the inserted (I)-domain, containing the metal ion-dependent adhesion site at the N-terminus of the CD11b (␣ M ) subunit. 20, 21, 34 VN binding to Mac-1 was dose-dependently inhibited by FBG, and VN could competitively inhibit FBG binding to Mac-1, indicating that the I-domain in the ␣ M subunit was also the putative binding site for VN.
uPAR can associate with Mac-1 and thereby regulate leukocyte adhesion on endothelial cells, ICAM-1, or FBG. 12, 23, 24, 35 uPAR is also involved in the regulation of cell adhesion on VN in an integrin-independent 36,37 manner attributable to an activation of Mac-1 by uPAR and vice versa. 24 Our current results suggest that in these previous studies, enhanced cell adhesion on VN in the presence of Mac-1 and uPAR could be attributable to a direct binding of Mac-1 to VN and not necessarily attributable to a transactivation of Mac-1 or uPAR itself. This information could have wide-ranging implications for studies on leukocyte-endothelial interactions in which an interaction between Mac-1 and uPAR has been postulated. 23, 38 When cultured in serumcontaining medium, cells may have surface-bound serumderived VN that binds uPAR and Mac-1, thereby influencing cell adhesion. Thus, concomitant binding of the 2 receptors to different domains of VN could enhance adhesion in a cooperative manner without altering the affinity or the recruitment of one or the other receptor.
Bone marrow-derived polymorphonuclear granulocytes obtained from CD18-deficient or WT mice exhibited no difference in adhesion on VN. 39 In this particular study, it was concluded that CD18 is not involved in cell adhesion on VN or FN. A major difference to our study is the type of cells used, and this could account for the differing results. On the other hand, PMN from patients with a defect in ␤ 2 integrins (leukocyte adhesion deficiency) exhibits diminished tyrosine phosphorylation of paxillin on VN and FN. 40 Although this result was interpreted to be a result of the missing proactive influence of ␤ 2 integrins on ␤ 1 and ␤ 3 integrins, it could also be explained by a loss of the direct interaction between Mac-1 and VN or FN. FN also seems to bind directly to Mac-1, 10 and we have observed that FN also competes for VN binding to Mac-1 (data not shown).
To directly define the interaction between Mac-1 and VN, we evaluated the adhesion of Mac-1-transfected CHO cells on VN. Using this system, we could confirm the direct interaction between Mac-1 and VN. In addition, the finding that the mutated, high-affinity Mac-1 demonstrates an increased adhesion further supports the notion of "integrin- Peripheral blood-derived neutrophils adhered to a VNcoated substrate in a CD18-dependent manner, indicating a physiological role for the Mac-1-VN interaction. Furthermore, the migration of neutrophils toward a chemotactic gradient of FMLP on a VN substrate was also Mac-1 dependent. The anti-VN antibody (mAb 13H1) that recognizes multimeric VN could reduce migration on a VN matrix but not an FBG matrix, indicating that the Mac-1-VN interaction is potentially involved in neutrophil migration. An anti-uPAR antibody (R3) that inhibits VN binding to uPAR 28 did not influence cell migration. Thus, the preferred cellularbinding partner for migration on a VN matrix is Mac-1 but not uPAR. It is possible that other Mac-1 functions, such as phagocytosis, are also influenced by VN. Also, VN may regulate signal transduction pathways through Mac-1.
In normal vessels, only minimal levels of VN can be detected by immunohistochemistry. However, high-level expression of VN could be shown in atheromatous plaques and in injured vessels. 17, 18 VN also leaks from blood into the extravascular tissue in situations of increased vascular permeability. 16 CD18-deficient mice exhibit a blunted inflammatory response in vivo. 41 To our knowledge, VN-deficient mice have not been tested in this regard. Leukocyte accumulation has an important function in the overall changes in vascular remodeling, and indeed in Mac-1-deficient mice, neointima formation after vascular injury is decreased. 42 For the role of VN in neointima formation, conflicting results have been reported. One study argues for an inhibition of neointima formation by VN, 43 whereas another argues for a promotion of neointima formation by VN. 18 In conclusion, we have characterized a direct interaction between VN and the ␤ 2 integrin Mac-1. The multimeric form of VN, which is the conformation found in the matrix (eg, in atherosclerotic plaques in contrast to the soluble monomeric form found in plasma) could be identified as a Mac-1 ligand. The nonactivated, low-affinity Mac-1 receptor is able to bind multimeric VN. However, the high-affinity Mac-1 receptor reveals a stronger binding to VN, indicating that affinity modulation of Mac-1 directly regulates Mac-1-VN binding. Overall, these findings suggest that the direct interaction between Mac-1 and VN is involved in the regulation of leukocyte adhesion and migration that may be relevant for vascular diseases that are characterized by high expression/ deposition of VN. After an incubation period of 2 h at 37°C, the upper side of the membrane was scraped to remove all cells. Thereafter, the membrane was fixed in acetone/methanol for 30 min at 22°C
and stained in a 5% (wt/vol) solution of crystal violet. After extensive washing, the number of cells on the lower side of the membrane was quantified by evaluation of the optical density of each well. 
